ω-3 Ethyl ester results in better cognitive function at 12 and 30 months than control in cognitively healthy subjects with coronary artery disease: a secondary analysis of a randomized clinical trial

• Published in: The American journal of clinical nutrition Vol. 113; no. 5; pp. 1168 - 1176
• Main Authors: Malik, Abdulaziz, Ramadan, Amira, Vemuri, Bhavya, Siddiq, Wardah, Amangurbanova, Maral, Ali, Aamir, Welty, Francine K
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.05.2021; American Society for Clinical Nutrition, Inc; Oxford University Press
• Subjects: Adults; Aged; Cardiovascular disease; Clinical trials; Cognition - drug effects; Cognitive ability; cognitive function; cognitively healthy; Coordination; Coronary artery; Coronary artery disease; Coronary Artery Disease - drug therapy; Coronary vessels; Diabetes mellitus; docosahexaenoic acid; Docosahexaenoic Acids - administration & dosage; Docosahexaenoic Acids - chemistry; Docosahexaenoic Acids - pharmacology; eicosapentaenoic acid; Eicosapentaenoic Acid - administration & dosage; Eicosapentaenoic Acid - chemistry; Eicosapentaenoic Acid - pharmacology; Esters; Ethyl esters; Fatty acids; Female; Heart diseases; Humans; Language; Male; Measuring techniques; Medical treatment; Memory; Middle Aged; Motor ability; Older people; omega-3 fatty acids; Original Research Communications; Psychology; Risk analysis; Risk factors; Secondary analysis; Sensitivity analysis; Sensorimotor integration; cognitive function; coronary artery disease; DSST; eicosapentaenoic acid; cognitively healthy; docosahexaenoic acid; MMSE; CAD; omega-3 fatty acids; TMT; COWAT; RAVLT

Omega-3 (n–3) fatty acids have shown benefit in cognitively impaired subjects, but the effect on cognitively healthy older subjects is unclear. Our aim was to determine if long-term, high-dose ω-3 ethyl esters, EPA (20:5n–3) and DHA (22:6n–3), prevent deterioration of cognitive function in cognitive...